Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-15

Study Completion Date

2034-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.

Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Recommendations for the Treatment of Children With Burkitt's Lymphoma

NCT04425421

Burkitt Lymphoma

RECRUITING

Therapy for Pediatric Hodgkin Lymphoma

NCT00145600

Hodgkin Lymphoma

COMPLETED PHASE2

A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)

NCT00592111

Pediatric Hodgkin's Disease

COMPLETED PHASE2

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

NCT03500133

Pediatric Hodgkin's Disease

RECRUITING PHASE4

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

NCT00002757

Leukemia Lymphoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In high-income countries, therapeutic outcomes exceed 90% and therapeutic de-escalation is necessary to reduce mainly the effects of long-term radiotherapy. Within the same country, there are also differences between the therapeutic protocols used in the different centres.

The Experience of Sub-Saharan African Units of the Franco-African Paediatric Oncology Group (GFAOP) in the treatment of pediatric Hodgkin lymphoma in 104 patients was based on chemotherapy alone. The latter was based on COPP/ABV cures without complementary irradiation adapted to the initial stratification and modulated according to the morphological response. Overall survival at 5 years was 82% at 30 months after a median decrease of 17 months.

It seemed appropriate to bring together in a single committee the representatives of the various pilot units in order to standardize the therapeutic protocols in the African countries.

So with this recommendation the GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data.

\- Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Staging Therapeutic Recommendations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational

Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

under 18 years of age at diagnosis

* suffering from "classical" Hodgkin's disease according to the WHO classification.
* with no history of hematological malignancies or constitutional or acquired immune deficiencies

Exclusion Criteria

* Over 18 years of age at diagnosis
* A history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies

Minimum Eligible Age

0 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No